首页> 外文期刊>Breast cancer research and treatment. >Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.
【24h】

Characteristics and spectrum of BRCA1 and BRCA2 mutations in 3,922 Korean patients with breast and ovarian cancer.

机译:3,922名韩国乳腺癌和卵巢癌患者中BRCA1和BRCA2突变的特征和光谱。

获取原文
获取原文并翻译 | 示例
           

摘要

This investigation is aimed at evaluating the epidemiologic characteristics of BRCA1/2 germline mutations in Korean patients with breast and ovarian cancer (BOC). We analyzed the entire mutational data of BRCA1/2 genes in BOC patients who were tested in Korea since the first Korean report of BRCA1 mutation in 1995 with the exception of the data covered in the Korean Hereditary Breast Cancer (KOHBRA) study, the project launched in 2007 for establishing BRCA1/2 carrier cohorts in Korea. In total, BRCA1/2 gene mutations of 3,922 Korean BOC patients were evaluated, including the unpublished data of 2,139 breast cancer patients examined by four Korean institutions and the data of 1,783 BOC patients covered in ten previous reports. Overall, 420 (150 distinct) pathogenic mutations were identified, 211 (73 distinct) in BRCA1 and 209 (77 distinct) in BRCA2. The majority (134 of 150) of the distinct mutations resulted in premature termination codon of the BRCA1/2 translation. BRCA1 c.4186-1593_4676-1465del was the only large genomic rearrangements mutation. Out of 150 distinct BRCA1/2 mutations, 84 (56 %) mutations were considered specific to Korean BOC. Eighty-five BRCA1/2 mutations were detected in at least two unrelated patients. These recurrent mutations account for 84.5 % (355 of 420) of mutations detected in the Korean population. In the pooled mutational data of BRCA1/2 genes, this study discovered the prevalence of BRCA1/2 mutations in the Korean BOC patients is similar to those found in other ethnic groups. Large genomic rearrangements in BRCA1/2 genes were infrequently detected among the Korean patients with BOC. There were several BRCA1/2 mutation candidates for founder mutations. To further establish a Korean cohort for BRCA1/2 mutations, the nationwide KOHBRA study is in progress.
机译:这项研究旨在评估韩国乳腺癌和卵巢癌(BOC)患者中BRCA1 / 2种系突变的流行病学特征。我们分析了自1995年韩国首次报道BRCA1突变以来在韩国接受检测的BOC患者中BRCA1 / 2基因的完整突变数据,但该项目开展的韩国遗传性乳腺癌(KOHBRA)研究除外于2007年在韩国建立了BRCA1 / 2航空母舰群。总共评估了3,922名韩国BOC患者的BRCA1 / 2基因突变,包括由四个韩国机构检查的2,139名乳腺癌患者的未公开数据以及先前十份报告中涵盖的1,783名BOC患者的数据。总体上,鉴定出420个(150个不同)致病突变,BRCA1中211个(73个不同)和BRCA2中209个(77个不同)。大多数(150个中的134个)独特的突变导致BRCA1 / 2翻译的提前终止密码子。 BRCA1 c.4186-1593_4676-1465del是唯一的大型基因组重排突变。在150个不同的BRCA1 / 2突变中,有84个(56%)突变被认为是韩国BOC特有的。在至少两名无亲缘关系的患者中检测到85个BRCA1 / 2突变。这些反复发生的突变占韩国人口中检测到的突变的84.5%(420个中的355个)。在收集的BRCA1 / 2基因突变数据中,这项研究发现韩国BOC患者的BRCA1 / 2突变患病率与其他种族相似。在韩国BOC患者中,很少发现BRCA1 / 2基因发生大的基因组重排。建立者突变有几种BRCA1 / 2突变候选者。为了进一步建立针对BRCA1 / 2突变的韩国人群,正在进行全国性的KOHBRA研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号